Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01038011 | Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study | PHASE2 | COMPLETED | - | — | — | Jun 1, 2004 | Aug 1, 2006 | May 8, 2017 | 1 | Switzerland |
| Name | Type | Description |
|---|---|---|
| drug treatment | DRUG | - |
Inclusion criteria: •Male or non-pregnant women (only women who are post menopausal, surgically sterile or practicing a reliable method of contraception may be included) aged 20 years or more * Meeting the Modified New York diagnostic criteria for AS (Van der Linden S et al., 1984) * Symptoms of ac...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | vilamakitug |
| AbbVie, Inc. | ABBV | 1 | — | Upadacitinib |
| Pfizer Inc. | PFE | 1 | — | Tofacitinib |
| Novartis AG Sponsored ADR | NVS | 1 | — | Secukinumab |
| TScan Therapeutics, Inc. | TCRX | 1 | — | Undisclosed |